Autosomal Dominant Leukodystrophy

Development of two promising candidates for the first ADLD treatment

Autosomal Dominant Leukodystrophy (ADLD) is a rare fatal, adult-onset demyelinating disorder that presents in the 4th or 5th decade of life. ADLD patients experience significant disability during the course of the disease and usually survive for only ~10-15 years after the onset of symptoms. No treatment exists for this fatal disease, representing an urgent and unmet clinical need. ADLD is caused by a duplication of the lamin B1 gene, resulting in increased LMNB1 protein expression and the appearance of nuclear abnormalities. We have developed methodology to quantify those abnormalities by high content analysis with the ultimate goal to perform a high-throughput screen for modifiers of Lamin B1 expression and associated changes in nuclear structure.

In a high throughput screen of over 100,000 chemical compounds, we have identified two promising candidates for further development into the first ADLD treatments.

A high-throughput, high-content screen identified novel modulators of Lamin B1. LMNB1 overexpression results in characteristic nuclear abnormalities manifesting themselves as blebs, invaginations, and folding (Nmezi et al., 2020). We developed an image-based high-throughput assay to screen 100,000 compounds for reduction of lamin and correction of associated nuclear abnormalities (A). The screen identified novel agents that selectively reduce Lamin B1 and correct nuclear abnormalities without cytotoxicity (B).

Papers

 Rolyan H, Tyurina YY, Hernandez M, Amoscato AA, Sparvero LJ, Nmezi BC, Lu Y, Estecio MR, Lin K, Chen J, He RR, Gong P, Rigatti LH, Dupree J, Bayir H, Kagan VE, Casaccia P, Padiath QS. Defects of Lipid Synthesis Are Linked to the Age-Dependent Demyelination Caused by Lamin B1 Overexpression. J Neurosci. 2015;35(34):12002-17. Epub 2015/08/28. doi: 10.1523/JNEUROSCI.1668-15.2015. PubMed PMID: 26311780; PMCID: 4549407. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214339/

Nmezi B, Vollmer LL, Shun TY, Gough A, Rolyan H, Liu F, Jia Y, Padiath QS, Vogt A. Development and Optimization of a High-Content Analysis Platform to Identify Suppressors of Lamin B1 Overexpression as a Therapeutic Strategy for Autosomal Dominant Leukodystrophy. SLAS Discov. 2020;25(8):939-49. doi: 10.1177/2472555220915821. PubMed PMID: 32349647; PMCID: PMC7755098. https://pubmed.ncbi.nlm.nih.gov/32349647/

Click here and include “ADL” in the Additional Gift Instructions to support research at the UPDDI to continue the development of a much-needed treatment for this debilitating disease.